CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
about
T-cell lymphomas, a challenging disease: types, treatments, and future.Antibody-mediated delivery of therapeutics for cancer therapy.Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates.The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer.Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.A novel enediyne-integrated antibody-drug conjugate shows promising anti-tumor efficacy against CD30+ lymphomas.Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report and Review of the Literature.Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.Brentuximab vedotin: clinical updates and practical guidance.Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway.Antibody-Drug Conjugates for Cancer Therapy.Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting.Current status and future directions of cancer immunotherapy.Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.
P2860
Q30244553-2FAB9938-AB49-438B-8A5A-2A2258C20142Q38665425-E1A1781C-7236-46F1-B700-7975F1BFC9D8Q38708078-04D1804A-356D-4345-AF3E-77F509A19449Q38726286-1F20B3BF-C915-41C3-9A21-6E473D3A566DQ39338052-B2793936-87DD-460E-BFA3-F018A5FEE479Q39840956-DEEAB1F7-C057-4F75-8E60-DF140FFA25E3Q47098861-D506FF83-2B43-4A94-8284-565FA94BAB19Q47102763-715D8E8A-FFE2-4844-BD89-23CD7F6A061BQ47217500-8652C73E-2789-42C0-90BB-EC1207334D09Q47566909-AB253F43-91E4-49DA-8A9A-E410B17A870AQ47851750-6A179C9B-CCC0-4E58-B644-EFC3987280CBQ48099690-F59840AB-C8DC-4E95-AC61-A3D875A761D9Q48150809-0487B358-486F-48FC-B069-2918BAE72764Q48243258-94A25ABB-4FDA-426A-BADC-349AB2005BAAQ49282959-B02B5200-E4F2-4E10-AEB3-E3A9E8930022Q50938405-98318CDB-3BC4-4E18-8A4A-89F901C7BE9EQ51567596-A9BE2E13-6C64-487A-9B1B-2DB2652272C6Q53681641-D6A15A31-998D-4BAF-A1D6-0CC68079903DQ53739135-1CAB46B2-627C-49B8-835B-320393FAF309Q53786443-433EBF1E-4563-46AC-9147-910B9A275901Q54248543-6920755C-A849-4716-9B29-0793339669E5Q55070491-9B344CA4-BD4D-4DB4-8C8D-5EF3501792CAQ55094448-07C665DB-F9FA-4FB7-9AE3-525AAD47B410
P2860
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CD30 Downregulation, MMAE Resi ...... stance to Brentuximab Vedotin.
@ast
CD30 Downregulation, MMAE Resi ...... stance to Brentuximab Vedotin.
@en
type
label
CD30 Downregulation, MMAE Resi ...... stance to Brentuximab Vedotin.
@ast
CD30 Downregulation, MMAE Resi ...... stance to Brentuximab Vedotin.
@en
prefLabel
CD30 Downregulation, MMAE Resi ...... stance to Brentuximab Vedotin.
@ast
CD30 Downregulation, MMAE Resi ...... stance to Brentuximab Vedotin.
@en
P2093
P2860
P1476
CD30 Downregulation, MMAE Resi ...... stance to Brentuximab Vedotin.
@en
P2093
Cecile Donohue
Edward Newman
Jessie Hou
Robert Chen
Stephen J Forman
Susan E Kane
P2860
P304
P356
10.1158/1535-7163.MCT-15-0036
P577
2015-04-03T00:00:00Z